Advances in pharmacotherapy for allergic conjunctivitis
Allergic conjunctivitis is a common and potentially debilitating condition affecting
the conjunctiva, eyelids and cornea, and it is often associated with nonocular symptoms
and signs of rhinitis or sinusitis.
Quarterly Ora Newsletter - May 1, 2015
Customer Success Stories: Celebrating Your Big Wins in 2014-2015
Clinical Advances in Ocular Allergy
Researchers
are exploring
disease-modifying
treatment options
and not just
symptomatic relief.
Anti-allergic agent alcaftadine stronger in relief of ocular itching
Data may influence prescribing habits and formulary availability in future allergy seasons
Sampling New Targets for Allergy Therapy
Learning more about ocular allergy has revealed a host of potential allergic mediators for researchers to attack.
Two Decades In Translation
For 20 years, “Therapeutic Topics” has explored ocular disease. Here’s an update on where translational medicine stands today.
Ora-CAC®Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix's OTX-DP in Allergic Conjunctivitis
A drug-eluting punctum plug being evaluated by Ocular Therapeutix
Acquisition of Boston biotech for up to $120M a 'validation' of Ora's model
French drug developer NiCox S.A. last week announced plans to buy Aciex Therapeutics
ARVO Comes to The City of Magic
Highlights from the posters and papers presented at the 2014
ARVO meeting in Orlando.